Research programme: chitotriosidase inhibitors - Molecure
Latest Information Update: 16 Aug 2023
At a glance
- Originator Molecure
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Chitotriosidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Interstitial lung diseases; Non-alcoholic steatohepatitis
Most Recent Events
- 31 Jul 2023 Molecure plans preclinical studies in 2025 (Molecure pipeline; July 2023)
- 20 Jul 2023 Early research in Interstitial lung diseases in Poland (unspecified route) (Molecure pipeline; July 2023)
- 20 Jul 2023 Early research in Non-alcoholic steatohepatitis in Poland (unspecified route) (Molecure pipeline; July 2023)